RepliCel Life Sciences Inc logo

RepliCel Life Sciences Inc

OTCPK:REPCF (Canada)  
$ 0.04 +0.002035 (+4.99%) 10:08 PM EST
Volume:
-
Avg Vol (2M):
10.91K
Also Trade In:
Volume:
-
Avg Vol (2M):
10.91K

Business Description

Description
RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from Licensing fees.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.78
Equity-to-Asset -20.05
Debt-to-Equity -0.01
Debt-to-EBITDA -0.62
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -195.75
Distress
Grey
Safe
Beneish M-Score 6.59
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 48.87
9-Day RSI 48
14-Day RSI 47.63
6-1 Month Momentum % -17.77
12-1 Month Momentum % -43.63

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.13
Quick Ratio 0.13
Cash Ratio 0.02

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -18.9
Shareholder Yield % -38

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -388.92
Net Margin % -19.6
FCF Margin % -564.62
ROA % -10.9
ROIC % -111.36
ROC (Joel Greenblatt) % -3777.78

GF Value Rank

Name Current Vs Industry Vs History
PE Ratio N/A
N/A
N/A
PE Ratio without NRI 3.93
PEG Ratio 0.11
PS Ratio 9.17
EV-to-EBIT -52.71
EV-to-EBITDA -54.3
EV-to-Revenue 10.18
EV-to-FCF -1.8
Earnings Yield (Greenblatt) % -1.9
FCF Yield % -55.72